ArticleCureus2024
Fluorodeoxyglucose Positron Emission Tomography Evaluation of Chronic Recurrent Multifocal Osteomyelitis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic and therapeutic insights from a cohort of chronic recurrent multifocal osteomyelitis (CRMO) patients.BMC rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease that predominantly affects children and adolescents. Currently, CRMO diagnoses are based on a combination of clinical, radiological, pathological, and longitudinal findings. However, distinguishing CRMO from malignant bone tumors using imaging is occasionally challenging. Fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging characteristics in CRMO (specifically, the maximum standardized uptake value (SUVmax)) have been described previously. The lesions exhibited increased FDG uptake despite the benign nature of the disease; the SUVmax was notably high (4.90). These findings suggest that FDG/PET plays a limited role in the differential diagnosis of CRMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.